Current Status and Advances in Anti-Androgen Therapy for Triple-Negative Breast Cancer

Abstract

The heterogeneity of triple-negative breast cancer (TNBC) has spurred the exploration of precision therapies based on molecular subtypes, with the androgen receptor (AR)-positive subtype emerging as a potential therapeutic target. The treatment of AR-positive TNBC relies primarily on androgen receptor antagonists, such as enobosarm, bicalutamide, and enzalutamide. To enhance efficacy, researchers are investigating combination therapies that integrate anti-androgen agents with chemotherapy, immunotherapy, or PARP inhibitors. Additionally, studies have revealed that the AR signaling pathway regulates the tumor microenvironment, and AR inhibition may potentiate the efficacy of immune checkpoint inhibitors. However, anti-AR therapies face significant limitations and challenges due to multifaceted factors, necessitating further resolution. With continued advancements, AR-targeted therapy holds promise as a critical component of personalized treatment strategies for TNBC.

Keywords

Triple-negative breast cancer / Tumor microenvironment / Molecular subtype / Androgen receptor / Immunotherapy combinations

References

[1] Jiang YZ, Ma D, Suo C, et al.. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell., 2019, 35(3): 428-440.e425

[2] Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple-negative breast cancer. BMJ., 2023, 381e071674

[3] Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol., 2014, 232(2): 142-150

[4] Narayanan R, Ahn S, Cheney MD, et al.. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial-mesenchymal stem cell signaling. PLoS One., 2014, 9(7e103202

[5] Palmieri C, Linden H, Birrell SN, et al.. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol., 2024, 25(3): 317-325

[6] Gucalp A, Tolaney S, Isakoff SJ, et al.. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res., 2013, 19(19): 5505-5512

[7] Proverbs-Singh T, Feldman JL, Morris MJ, et al.. Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer., 2015, 22(3): R87-R106

[8] Dong S, Yousefi H, Savage IV, et al.. Ceritinib is a novel triple-negative breast cancer therapeutic agent. Mol Cancer., 2022, 21(1): 138

[9] Thomas C, Lamoureux F, Crafter C, et al.. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther., 2013, 12(112342-2355

[10] Lehmann BD, Abramson VG, Sanders ME, et al.. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR⁺ metastatic triple-negative breast cancer. Clin Cancer Res., 2020, 26(9): 2111-2123

[11] Liu CY, Lau KY, Hsu CC, et al.. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS One., 2017, 12(12e0189007

[12] Yang C, Jin J, Yang Y, et al.. Androgen receptor-mediated CD8⁺ T cell stemness programs drive sex differences in antitumor immunity. Immunity., 2022, 55(7): 1268-1283.e1269

[13] Thacker G, Henry S, Nandi A, et al.. Immature natural killer cells promote progression of triple-negative breast cancer. Sci Transl Med., 2023, 15(686eabl4414

[14] Yang F, Xiao Y, Ding JH, et al.. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab., 2023, 35(1): 84-100.e108

[15] Jung M, Kowalczyk K, Hankins R, et al.. Novel paired normal prostate and prostate cancer model cell systems derived from African American patients. Cancer Res Commun., 2022, 2(12): 1617-1625

[16] Zhang T, Wang B, Wei Y, et al.. Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study. Cell Rep Med., 2025, 6(3102018

[17] Luo J, Jin J, Yang F, et al.. The correlation between PARP1 and BRCA1 in AR-positive triple-negative breast cancer. Int J Biol Sci., 2016, 12(12): 1500-1510

[18] Xie J, Guo H, Dong B, et al.. Olaparib Combined with Abiraterone versus Olaparib Monotherapy for patients with metastatic castration-resistant prostate Cancer progressing after Abiraterone and harboring DNA damage Repair Deficiency: a Multicenter Real-world study. Eur Urol Oncol., 2024, 7(5): 1088-1096

[19] Brumec M, Sobočan M, Takač I, et al.. Clinical implications of androgen-positive triple-negative breast cancer. Cancers., 2021, 13(7): 1642

[20] Witzel I, Loibl S, Wirtz R, et al.. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer., 2019, 121(121009-1015

[21] Snyder LB, Neklesa TK, Willard RR, et al.. Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. Mol Cancer Ther., 2025, 24(4): 511-522

[22] You CP, Tsoi H, Man EPS, et al.. Modulating the activity of androgen receptor for treating breast cancer. Int J Mol Sci., 2022, 23(23): 15342

[23] Bonnefoi H, Lerebours F, Pulido M, et al.. Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3–06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol., 2025, 26(3355-366

[24] Abbasi A, Movahedpour A, Amiri A, et al.. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer. Curr Mol Med., 2021, 21(4): 332-346

[25] Hinova Pharmaceuticals Inc. Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment: Cision PR Newswire; 2023 [Available from: https://www.prnewswire.com/news-releases/hinova-receives-fda-proceed-authorization-for-its-ind-application-for-hp518-an-orally-bioavailable-chimeric-degrader-targeting-androgen-receptor-for-prostate-cancer-treatment-301739031.html].

[26] Zhang H, Yang Y, Cao Y, et al.. Effects of chronic stress on cancer development and the therapeutic prospects of adrenergic signaling regulation. Biomed Pharmacother., 2024, 175116609

[27] Traina TA, Miller K, Yardley DA, et al.. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol., 2018, 36(9): 884-890

[28] Michaels E, Chen N, Nanda R. The role of Immunotherapy in Triple-negative breast Cancer (TNBC). Clin Breast Cancer., 2024, 24(4): 263-270

[29] Veru Inc. Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024) 2021 [Available from: https://ichgcp.net/clinical-trials-registry/NCT05065411].

[30] Yuan Y, Lee JS, Yost SE, et al.. A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist., 2021, 26(2): 99-e217

[31] Wang J, Li Q, Xu B. Research progress of histone deacetylase inhibitors in HR-positive HER-2 negative advanced breast cancer. Chin J Clin Oncol., 2023, 50(17): 897-900

[32] Xu B, Zhang Q, Hu X, et al.. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Acta Pharm Sin B., 2023, 13(5): 2250-2258

[33] Zhao YX, Wang H, Zhang SW, et al.. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy. Cancer Cell Int., 2024, 24(1): 131

[34] Valencia GA, Rioja P, Morante Z, et al.. Immunotherapy in triple-negative breast cancer: A literature review and new advances. World J Clin Oncol., 2022, 13(3219-236

[35] Kolyvas EA, Caldas C, Kelly K, et al.. Androgen receptor function and targeted therapeutics across breast cancer subtypes. Breast Cancer Res., 2022, 24(1): 79

[36] Rodríguez M, Rodríguez IG, Nattress C, et al.. HDAC inhibitors enhance efficacy of the oncolytic adenoviruses Ad∆∆ and Ad-3∆-A20T in pancreatic and triple-negative breast cancer models. Viruses., 2022, 14(51006

[37] Kumar V, Yu J, Phan V, et al.. Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer. JCO Precis Oncol., 2017, 1: 1-19

[38] Li F, Niu M, Qin K, et al.. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance. Oncogene., 2023, 42(5339-350

[39] Liang Y, Wang Y, Zhang Y, et al.. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer. Cell Death Dis., 2023, 14(7): 434

[40] Liu CC, Chen L, Cai YW, et al.. Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell Rep Med., 2024, 5(2101396

[41] Yu L, Liebenberg K, Shen Y, et al.. Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. Immunity., 2025, 58(4909-925.e907

[42] Yang L, Shi P, Zhao G, et al.. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther., 2020, 5(1): 8

[43] Li MX, Hu S, Lei HH, et al.. Tumor-derived miR-9-5p-loaded EVs regulate cholesterol homeostasis to promote breast cancer liver metastasis in mice. Nat Commun., 2024, 15(110539

[44] Li Q, Ci H, Zhao P, et al.. NONO interacts with nuclear PKM2 and directs histone H3 phosphorylation to promote triple-negative breast cancer metastasis. J Exp Clin Cancer Res., 2025, 44(190

[45] Liu C, Sun L, Niu N, et al.. Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies. Signal Transduct Target Ther., 2025, 10(197

[46] Del Re M, Biasco E, Crucitta S, et al.. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol., 2017, 71(4680-687

[47] Hernandez JM, Feller A, Morohashi K, et al.. The basic helix loop helix domain of maize R links transcriptional regulation and histone modifications by recruitment of an EMSY-related factor. Proc Natl Acad Sci U S A., 2007, 104(43): 17222-17227

[48] Huynh CG, Huynh NX, Truong HBT, et al.. PD-L1 and TILs expression and their association with clinicopathological characteristics in Vietnamese women with primary invasive breast cancer. Medicine (Baltimore)., 2023, 102(26e34222

[49] Zhang Y, Gao Y, Jiang Y, et al.. Histone demethylase KDM5B licenses macrophage-mediated inflammatory responses by repressing Nfkbia transcription. Cell Death Differ., 2023, 30(5): 1279-1292

[50] He B, Bie Q, Zhao R, et al.. Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling. Cell Rep Med., 2024, 5(5101510

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology